Clinical trial
Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine
NCT00290147 · U.S. Army Medical Research and Development Command, U.S. Fed · Completed
Key facts
| NCT number | NCT00290147 |
|---|---|
| Title | Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine |
| Official title | An Open-Label, Dose Escalation, Phase I Safety, and Immunogenicity Trial of a Dengue Serotype 1 (DEN-1) Premembrane (prM) and Envelope (E) DNA Vaccine (D1ME100) in Healthy Adults Volunteers |
| Lead sponsor | U.S. Army Medical Research and Development Command, U.S. Fed |
| Collaborators | United States Army Medical Materiel Development Activity U.S. Fed |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Dengue |
| Intervention type | Biological |
| Interventions | D1ME100 (dengue-1 premembrane/envelope DNA vaccine) |
| Enrollment | 22 |
| Start date | Jan 1, 2006 |
| Primary completion | Dec 1, 2006 |
| Completion | Apr 1, 2009 |
| First posted | Feb 10, 2006 |
| Last update posted | Jun 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: